Castle Biosciences, Inc.

NasdaqGM CSTL

Castle Biosciences, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2024: USD -24.55 M

Castle Biosciences, Inc. Capital Expenditure is USD -24.55 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -111.38% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Castle Biosciences, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -11.62 M, a -145.15% change year over year.
Castle Biosciences, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -4.74 M, a -49.04% change year over year.
Castle Biosciences, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -3.18 M, a 29.50% change year over year.
Castle Biosciences, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -4.51 M.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NasdaqGM: CSTL

Castle Biosciences, Inc.

CEO	Mr. Derek J. Maetzold
IPO Date	July 25, 2019
Location	United States
Headquarters	505 South Friendswood Drive
Employees	710
Sector	Healthcare
Industries Biotechnology Big Data

Description

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.

Key trends

Past 5 years